Sirtex yet to peak: Wong

Sirtex Medical (ASX:SRX) was one of the blockbuster stocks of the 2012, with it posting a 193% gain over the calendar year, from $4.50 at the year’s opening to $13.20 at year’s end.

This made it the second best performing stock on the ASX, just pipped at the line by Maverick Drilling (ASX: MAD).

Yet Sirtex CEO Gilman Wong has expressed confidence that the company still has plenty of growth left in it.

This comes off the back of news that its flagship product, SIR-Spheres, have enjoyed a 25% boost in dose sales for the quarter ending 31 December 2012 compared with the similar quarter in 2011.

This represents the 34th consecutive quarter of growth experienced by the company since 2004.

Sales grew in all regions, including 37% in Europe, the Middle East and Africa, and even saw 29% growth over the quarter in the beleaguered United States.

“I am pleased with this result,” said Wong. “All four quarters during the 2012 calendar year were very strong and have set a very high benchmark for the 2013 quarters.

“However, I am confident that our growth performance of the last five years will be maintained.”

Sirtex (ASX:SRX) last traded at $12.56, down 3.3% for the day, as of around midday Wednesday.